Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 16/20 | 0.75 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.51 |
| ▸ | SMO | Q99835 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30429642 | 1.00 | KMO (0.75) | KMOGRM4SMOGRM5 | |
| SCHEMBL1939335 | 0.89 | KMO (0.65) | KMOSMOGRM5 | |
| SCHEMBL30429046 | 0.89 | KMO (0.65) | KMOSMOGRM5 | |
| SCHEMBL1937820 | 0.88 | KMO (0.76) | KMOGRM4 | |
| SCHEMBL1939250 | 0.88 | KMO (0.72) | KMOGRM4SMO | |
| SCHEMBL30429041 | 0.88 | KMO (0.72) | KMOGRM4SMO | |
| SCHEMBL30459265 | 0.87 | KMO (0.79) | KMOGRM4SMO | |
| SCHEMBL1938295 | 0.87 | KMO (0.79) | KMOGRM4SMO | |
| SCHEMBL14742201 | 0.87 | KMO (0.61) | KMOSMOGRM5 | |
| SCHEMBL1939398 | 0.86 | KMO (0.77) | KMOGRM4SMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130331370-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | WITYAK JOHN (US) | 2013-12-12 | — | — | US | claimed |
| US-20110183957-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-07-28 | — | — | US | claimed |
| EP-2331095-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, Inc. (US) | 2011-06-15 | — | — | EP | claimed |
| WO-2010017179-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2010-02-11 | — | — | WO | claimed |
| US-12036292-B2 | Heterobiaryl compounds and imaging agents for imaging huntingtin protein | CHDI FOUNDATION, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| EP-4192819-A1 | HETEROBIARYL COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | CHDI Foundation, Inc. (US) | 2023-06-14 | — | — | EP | disclosed |
| US-20220040336-A1 | HETEROBIARYL COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | CHDI FOUNDATION, INC. | 2022-02-10 | — | — | US | disclosed |
| US-9428464-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9428464-B2 | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2016-08-30 | — | — | US | disclosed |
| US-9145373-B2 | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2015-09-29 | — | — | US | disclosed |
| US-20140329795-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2014-11-06 | — | — | US | disclosed |
| US-20140329795-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2014-11-06 | — | — | US | disclosed |
| EP-2331095-B1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2014-10-15 | — | — | EP | disclosed |
| US-20130331370-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | WITYAK JOHN (US) | 2013-12-12 | — | — | US | disclosed |
| US-8536186-B2 | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | CHDI FOUNDATION, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20110183957-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI FOUNDATION, INC. | 2011-07-28 | — | — | US | disclosed |
| EP-2331095-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, Inc. (US) | 2011-06-15 | — | — | EP | disclosed |
| WO-2010017179-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | CHDI, INC. (US) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183957-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | KMO 1/4885GRM4 331/4885SMO 2540/4885 |
| US-20220040336-A1 | HETEROBIARYL COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEIN | HTT, HYPK, ATXN2L | KMO 4249/4885GRM4 932/4885SMO 3074/4885 |
| US-20140329795-A1 | KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, HAAO | KMO 1/4885GRM4 352/4885SMO 2501/4885 |
| US-20130331370-A1 | CERTAIN KYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | KMO, KYNU, MAOA | KMO 1/4885GRM4 331/4885SMO 2540/4885 |
| US-12036292-B2 | Heterobiaryl compounds and imaging agents for imaging huntingtin protein | HTT, HYPK, ATXN2L | KMO 4249/4885GRM4 932/4885SMO 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.